AC Immune SA (ACIU)
| Market Cap | 280.74M +68.4% |
| Revenue (ttm) | 4.62M -86.9% |
| Net Income | -82.55M |
| EPS | -0.82 |
| Shares Out | 99.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 78,141 |
| Open | 2.870 |
| Previous Close | 2.850 |
| Day's Range | 2.815 - 2.910 |
| 52-Week Range | 1.600 - 4.000 |
| Beta | 1.65 |
| Analysts | Strong Buy |
| Price Target | 8.93 (+215.55%) |
| Earnings Date | Apr 30, 2026 |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow A... [Read more]
Financial Performance
In 2025, AC Immune's revenue was 3.57 million, a decrease of -86.92% compared to the previous year's 27.31 million. Losses were -70.45 million, 38.4% more than in 2024.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ACIU stock is "Strong Buy." The 12-month stock price target is $8.93, which is an increase of 215.55% from the latest price.
News
AC Immune presents new Phase 1 data on uptake of ACI-19626
AC Immune (ACIU) SA announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography tracer ACI-19626 showing increased uptake in the…
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients ...
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appoi...
AC Immune reports Q1 EPS (15c), consensus (14c)
Reports Q1 revenue $1.12M, consensus $263,230. Andrea Pfeifer, CEO of AC Immune (ACIU) SA, commented: “The progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our…
AC Immune First Quarter 2026 Financial and Corporate Updates
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteer...
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 ...
AC Immune Earnings release: Q1 2026
AC Immune released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
AC Immune Slides: Investor presentation
AC Immune has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Leerink calls AC Immune- Eli Lilly Tau amendment ‘great news’
Leerink analyst Marc Goodman says AC Immune’s (ACIU) amendment of the collaboration agreement with Eli Lilly (LLY) for the Morphomer Tau program is “great news” and underscores the continued interest…
AC Immune announces amendment to Eli Lilly license pact, to receive CHF 10M
AC Immune (ACIU) announced an agreement with Eli Lilly (LLY) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential...
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significa...
AC Immune’s PET tracer shows efficacy detecting brain pathologies
AC Immune (ACIU) announced the presentation of Phase 1 data including the first in vivo images of TDP-43 pathology in the human brain, detected using its positron emission tomography –…
AC Immune reports FY25 EPS (CHF 0.70) vs (CHF 0.51) last year
Reports FY25 revenue CHF 3.753M vs CHF 27.309M last year. Dr. Andrea Pfeifer, CEO of AC Immune (ACIU) SA, commented: “We made significant progress towards delivering precision prevention of neurodegen...
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's ...
AC Immune Earnings release: Q4 2025
AC Immune released its Q4 2025 earnings on March 13, 2026, summarizing the period's financial results.
AC Immune Annual report: Q4 2025
AC Immune has published its Q4 2025 annual report on March 13, 2026.
AC Immune Slides: Investor presentation
AC Immune has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
AC Immune initiates Phase 1 trial of NLRP3 inhibitor
AC Immune (ACIU) announced that the first participant has been dosed in a Phase 1 clinical trial of ACI-19764, an orally administered small molecule inhibitor of the NLRP3 inflammasome. Targeting…
AC Immune Transcript: Study Update
Interim phase 2 results for ACI-7104 in early Parkinson's disease show strong safety, robust antibody response, and stabilization of key biomarkers and motor symptoms, suggesting potential disease modification. Plans are underway to accelerate development and expand future trials.
AC Immune Press release: Study Update
AC Immune issued a press release on December 11, 2025, disclosing material business information to investors.
AC Immune Slides: Study Update
AC Immune has posted slides in relation to its latest quarterly earnings report, which was published on December 11, 2025.
AC Immune’s Parkinson’s disease candidate shows positive Phase 2 results
AC Immune (ACIU) announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein active immunotherapy ACI-7104.056 in early Parkinson’s di...
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease
The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD.
AC Immune Transcript: Jefferies London Healthcare Conference 2025
The conference highlighted a robust pipeline in neurodegenerative disease, emphasizing precision medicine, active immunotherapy, and small molecule innovation. Key data readouts and clinical milestones are expected by year-end, supporting both partnered and wholly owned programs.